MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder

3,4-Methylenedioxymethamphetamine (MDMA) is described as an entactogen with a pharmacological profile that preferentially affects the emotional sphere, and it has a history of psychotherapeutic use prior to its prohibition in the 1980s. Earlier, largely uncontrolled clinical and anecdotal reports suggested MDMA could facilitate access to traumatic memories by reducing fear and anxiety, thereby strengthening the therapeutic alliance and potentially improving outcomes in disorders such as posttraumatic stress disorder (PTSD). However, formal, government‑approved controlled data in clinical populations were scarce at the time this study was initiated. This study set out to investigate the safety of single, ascending doses of MDMA administered as an adjunct to psychotherapy in women with chronic, treatment‑resistant PTSD secondary to sexual assault, and to obtain preliminary efficacy data. The trial was approved by the Ethics Committee of University Hospital La Paz and the Spanish Ministry of Health. Although the original protocol planned to enrol 29 participants across five dose levels, political decisions led to an early termination after only six subjects had been treated; the paper therefore reports preliminary findings from that small sample.

The treated sample comprised six women recruited in Madrid between 2000 and 2002, aged 29–49 years, weighing 50–61.3 kg, with no prior MDMA experience. All were physically healthy on medical screening, had a primary diagnosis of chronic PTSD (secondary to sexual assault) with prior non‑response to at least one standard treatment, and were free of psychotropic medication for at least one month before the experimental session. Negative pregnancy tests were required immediately prior to drug administration. The original study design was a double‑blind, ascending‑dose, randomised, placebo‑controlled trial planned to test five single oral MDMA doses (50, 75, 100, 125, 150 mg) across 29 women. Dose escalation was to proceed only after completion of earlier dose cohorts. Because the trial closed early, the six treated participants were distributed as follows: subjects 1, 3 and 4 received 50 mg MDMA; subject 5 received 75 mg MDMA; subjects 2 and 6 received placebo. An independent evaluator, blind to treatment, performed psychological assessments. Psychotherapeutic procedures included three 90‑minute preparatory nondrug sessions, a single experimental session comprising six hours of psychotherapy plus two hours of rest (therapists present throughout; blood pressure and heart rate measured every 30 minutes during the first six hours), and three 90‑minute integration sessions afterwards. An additional brief session occurred the day after the experimental session. Therapists were a male–female pair for each subject, and therapy emphasised preparation, relaxation techniques, controlled re‑experiencing of trauma, and post‑session integration. Follow‑ups were planned at 1, 3, 6, 9 and 12 months, but participant contact was incomplete: subjects 1, 3, 4 and 5 attended the first follow‑up; subjects 4 and 5 attended the second; only subject 4 attended the third; no one completed the 12‑month follow‑up. Outcome measures covered PTSD symptoms and related psychopathology. The primary PTSD instrument was the Severity of Symptoms Scale for Post‑traumatic Stress Disorder (SSSPTSD), a Spanish adaptation of the PSS with global and subscale scores for re‑experiencing, avoidance, increased arousal and somatic symptoms. Secondary measures included the State‑Trait Anxiety Inventory, State version (STAI‑S), Beck Depression Inventory (BDI), Hamilton Depression Rating Scale (HAM‑D), Modified Fear Scale (MFS III, sexual‑assault specific items), a social/maladjustment scale (MS), and the Rosenberg Self‑Esteem scale (SE/R). Subjective acute effects were measured with the Hallucinogen Rating Scale (HRS), side effects with the UKU scale, and therapeutic alliance with the Penn Helping Alliance Questionnaire (HAq). Because only six subjects were treated, the investigators report descriptive results only and did not perform inferential statistical comparisons.

Demographic data indicated a heterogeneous sample in education and assault type: ages 29–49, one with no formal schooling, three with elementary education, one with secondary and one with university studies; sexual assaults reported included anal rape (2), vaginal rape (2) and other forms of sexual aggression (2). Treatment allocation was as stated above (three at 50 mg, one at 75 mg, two on placebo). Subject 5 (75 mg) reported greater acute subjective effects on the HRS than any of the 50 mg recipients and showed the largest improvements on most outcome measures. On the SSSPTSD, subject 5 improved by 16 points from pre‑ to post‑treatment, by 17 points from pre‑treatment to the first follow‑up (compared with 12.3 points for the 50 mg group), and by 20 points from pre‑treatment to the second follow‑up. The authors report that, overall, the 50 mg group improved more than the placebo group on PTSD symptoms, and that subject 5 tended to show greater reductions in state anxiety (STAI‑S), depression (BDI and HAM‑D), and fear (MFS III) than both the 50 mg and placebo participants. Therapeutic alliance scores (HAq) increased from pre‑ to post‑treatment for all subjects except subject 6, although the authors note no clear evidence that this change was specifically related to the experimental session. Side‑effect monitoring with the UKU scale found only very mild effects reported by subjects 1 (50 mg) and 5 (75 mg) at 24 hours; no notable side‑effect reports were recorded at seven days. Cardiovascular monitoring showed no consistent or clinically significant increases in blood pressure or heart rate compared with baseline for the group as a whole. Subject 4 met criteria for transient tachycardia (fast heart rate) and hypertension at some time points during the session, but the investigators considered these elevations within ranges previously reported in MDMA studies and not requiring medical intervention. Blinding appeared broadly effective at these low doses: therapists and patients often misidentified whether MDMA or placebo had been administered and estimated dose inaccurately, suggesting that the double‑blind condition held for low doses in this sample. Because of the small sample size, incomplete follow‑up data and absence of statistical testing, the results are presented descriptively and are preliminary.

Bouso and colleagues present this trial as the first fully approved, controlled study to examine MDMA administration in a patient population. The authors interpret their findings as indicating that low single doses of MDMA (50–75 mg) administered during a structured psychotherapeutic protocol were both psychologically and physiologically safe in the six treated women with chronic PTSD. They highlight that no subject showed increased scores on the re‑experiencing subscale after treatment or at follow‑up, alleviating a principal safety concern about retraumatisation during exposure‑based work. In terms of efficacy signals, the 75 mg recipient showed larger subjective effects and larger reductions on PTSD and other psychopathology scales than the 50 mg recipients and the placebo cases; the 50 mg group exceeded placebo on PTSD symptom change. From these descriptive observations the investigators suggest a possible dose–response relationship within the studied range, and recommend investigation of higher therapeutic doses in larger samples. The discussion places the findings in the context of concurrently developing MDMA‑assisted therapy trials using larger doses (for example 125 mg with optional supplemental dosing) and notes preliminary safety data from those efforts. The authors acknowledge important limitations: the study was terminated early for non‑scientific political reasons and therefore enrolled only six of the planned 29 participants, follow‑up data were incomplete, and the sample size precluded statistical analyses or definitive conclusions about efficacy or dose‑response for physiological measures. They also note variability across measures that prevents establishing a reliable cardiovascular dose‑response in this dataset. The paper concludes that, while low doses appeared safe in this very small sample and some promising clinical changes were observed, adequately powered trials with larger samples and testing of higher doses are necessary to clarify both safety and efficacy of MDMA‑assisted psychotherapy in PTSD.